Analyst maintains an Outperform rating with a $220 price forecast and says Williams-Sonoma is well-positioned to navigate challenges with diversified brand portfolio, strong supply chain, and flexible costs.
Johnson & Johnson's Phase 3b APEX study shows Tremfya reduces symptoms and structural damage in psoriatic arthritis patients with no new safety concerns.
Iron ore set for declines, Goldman Sachs predicts. Chinese steel demand down 5% in 2025, exports to fall 15% due to tariffs. Australia faces economic threat.
Goldman Sachs analyst Michael Ng maintains a Neutral rating on Warner Bros Discovery (NASDAQ: WBD) with a $10.75 price target. The Q1 EBITDA estimate is now $2.03 billion (previously $2.08B), with revenue lowered to $9.54B. Lower ARPU and weaker box office performance impacted projections, though subscriber growth and international expansion could drive future gains.
Looking for insights into the US markets in the middle of the day on Friday? Delve into the top gainers and losers of today's session and gain valuable market intelligence.
